ClinicalTrials.gg
Not yet recruitingNCT07804381ARREST-PDUpdated Sep 10, 2026

Disease-modifying Efficacy of Sitagliptin Therapy in Early-stage Parkinson's Disease

A Phase 2 interventional study of Sitagliptin and Sitagliptin placebo in Parkinson Disease, sponsored by Yonsei University. Not yet recruiting. Open to participants aged 50 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-09-10.

Sponsored by Yonsei University · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
160
Allocation
Randomized
Ages
50 Years to 80 Years
Sex
All
01

Study summary

Parkinson's disease (PD) is a progressive neurodegenerative disorder pathologically characterized by the loss of dopaminergic neurons in the substantia nigra pars compacta and the accumulation of α-synuclein (α-syn) aggregates. To date, all approved treatments, including levodopa, are primarily limited to symptomatic relief, and no disease-modifying therapy (DMT) has been established to fundamentally slow or halt disease progression.

Large-scale epidemiological cohort studies conducted in Taiwan, Sweden, the United Kingdom, and other countries have consistently reported that, among patients with diabetes, DPP-4 inhibitor users had an approximately 30%-40% lower risk of developing Parkinson's disease compared with non-users.

This study aims to evaluate whether 72 weeks of treatment with sitagliptin (100 mg once daily), compared with placebo, delays the time to confirmed motor progression in patients with early-stage PD receiving stable levodopa monotherapy. Confirmed motor progression is defined as an increase of ≥5 points from baseline in the Movement Disorder Society-Unified Parkinson's Disease Rating Scale (MDS-UPDRS) Part III score assessed in the OFF state.

02

Conditions studied

  • Parkinson Disease

Browse trials for

03

In context

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

This study's planned enrollment of 160 is above the median of 40 across 3,357 interventional studies indexed under Parkinson Disease.

Browse Parkinson Disease studies →

Lead sponsor

Yonsei University is the lead sponsor of 1,420 studies on the registry; 242 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
50 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female participants aged 50 to 80 years, inclusive.
  2. Participants diagnosed with Clinically Established Parkinson's Disease or Clinically Probable Parkinson's Disease according to the Movement Disorder Society (MDS) Clinical Diagnostic Criteria for Parkinson's Disease (Postuma et al., 2015).
  3. Participants diagnosed with Parkinson's disease within 3 years prior to screening.
  4. Participants who are either treatment-naïve to antiparkinsonian medications at screening or receiving stable levodopa monotherapy, defined as maintenance of the same levodopa dose for at least 12 weeks immediately prior to screening without concomitant use of other antiparkinsonian medications.
  5. Hoehn and Yahr stage 1 or 2 in the ON state.
  6. Participants with documented evidence, based on ¹⁸F-FP-CIT PET performed at the site within 36 months prior to screening, of reduced dopamine transporter (DAT) availability in the posterior putamen. Raw DICOM files must be retrievable and suitable for quantitative analysis of standardized uptake value ratio (SUVR) or specific binding ratio (SBR) by the central reader. Participants without an available prior ¹⁸F-FP-CIT PET result must agree to undergo an additional ¹⁸F-FP-CIT PET scan.
  7. Participants with documented brain MRI performed at any time prior to screening or during the screening period, confirming exclusion of causes other than Parkinson's disease, including atypical parkinsonian syndromes such as multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), cerebrovascular disease, normal-pressure hydrocephalus, and brain tumor. The T1-weighted sequence must be suitable for comparison with the follow-up MRI performed at Visit 9.
  8. (MMSE) score ≥24, to exclude severe cognitive impairment.
  9. Participants who understand the clinical trial protocol and voluntarily provide written .
  10. Participants who are able and willing to comply with follow-up visits and study assessments throughout the entire study period.

Exclusion criteria

Exclusion Criteria:

  1. Participants with suspected atypical parkinsonian syndromes, including progressive supranuclear palsy (PSP), multiple system atrophy (MSA), corticobasal syndrome (CBS), or other atypical parkinsonian disorders.
  2. Participants with vascular parkinsonism, drug-induced parkinsonism, or toxin-induced parkinsonism.
  3. Participants with secondary parkinsonism due to causes such as normal-pressure hydrocephalus, brain tumor, or other identifiable secondary causes.
  4. Participants currently receiving dopaminergic medications other than levodopa, including dopamine agonists, monoamine oxidase-B (MAO-B) inhibitors, catechol-O-methyltransferase (COMT) inhibitors, amantadine, or other antiparkinsonian medications.
  5. Participants with levodopa-induced motor fluctuations or levodopa-induced dyskinesia (LID) that interfere with activities of daily living, defined as a score of ≥2 on MDS-UPDRS Part IV Item 4.1 or 4.2.
  6. History of to sitagliptin or any other dipeptidyl peptidase-4 (DPP-4) inhibitor.
  7. Current treatment with a DPP-4 inhibitor or glucagon-like peptide-1 (GLP-1) receptor agonist.
  8. History of acute or chronic pancreatitis.
  9. Acute cholecystitis or cholangitis.
  10. Participants with previously diagnosed diabetes mellitus who are currently receiving antidiabetic medication.However, participants with a diagnosis of diabetes mellitus who are not currently receiving antidiabetic medication, or those found to have ≥6.5% during screening, may be enrolled. Participants with HbA1c ≥7.5% will be excluded because combination antidiabetic therapy may be required.
  11. Estimated (eGFR) \<45 mL/min/1.73 m², indicating moderate or greater renal impairment.
  12. Hepatic dysfunction, defined as or ALT >3 times the (ULN).
  13. Pancreatic enzyme abnormality, defined as amylase or lipase >3 times the ULN.
  14. cardiovascular disease, including (NYHA) Class III-IV heart failure, myocardial infarction, or stroke within 6 months prior to screening.
  15. History of within 5 years prior to screening, except for completely treated non-melanoma skin cancer.
  16. Uncontrolled, clinically significant psychiatric disorder.
  17. Participants who are pregnant or breastfeeding, or women of who are unwilling or unable to use an appropriate method of .
  18. Participation in another clinical trial within 30 days prior to screening.
  19. Participants considered unsuitable for participation in the clinical trial based on the investigator's clinical judgment.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
160 participants (estimated)

Study arms

  • Experimental
    Sitagliptin

    Sitagliptin 100 mg, one tablet orally once daily, with or without food, for 72 weeks.

    Drug: Sitagliptin

  • Placebo comparator
    Sitagliptin placebo

    One placebo tablet orally once daily, with or without food, for 72 weeks. (The placebo will be manufactured to be indistinguishable from the investigational product in terms of appearance, color, size, and weight in order to maintain blinding.)

    Drug: Sitagliptin placebo

Interventions

  • Sitagliptin 100 mg, one tablet orally once daily, with or without food, for 72 weeks.

  • DrugSitagliptin placebo

    One placebo tablet orally once daily, with or without food, for 72 weeks. (The placebo will be manufactured to be indistinguishable from the investigational product in terms of appearance, color, size, and weight in order to maintain blinding.)

06

What researchers measure

Primary outcomes

  1. Time to Confirmed Motor Progression (TTE)

    Time from randomization (V2) to the first observed increase of ≥5 points from baseline in the MDS-UPDRS Part III score, confirmed at the next scheduled visit (approximately 12 weeks later), assessed in the OFF state in the morning prior to levodopa administration and after ≥12 hours since the last levodopa dose.

    Time frame: From randomization every 12 weeks through Week 76.

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2026; primary completion for Mar 2029, 26 months later.

Of 105 non-industry phase 2 interventional studies under Parkinson Disease, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 26 months is below that.

Counting every sponsor, half of 202 studies reached it within 28 months; a quarter within 16 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2026
First posted
Sep 4, 2026
StartEst.
Dec 15, 2026
Primary completionEst.
Mar 1, 2029
CompletionEst.
Apr 1, 2029
Last update
Sep 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07804381
Lead sponsor
Yonsei University
Responsible party
Sponsor
First posted
Sep 4, 2026
Start date
Dec 15, 2026 (estimated)
Primary completion
Mar 1, 2029 (estimated)
Completion
Apr 1, 2029 (estimated)
Last update
Sep 10, 2026

Study contacts

Philhyu Lee, Professor
Contact
PHLEE@yuhs.ac
+82-2-2228-1608

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sitagliptin

Start the discussion